Physician profile
Logan Thimons
NPI 1265138242
$8,552.47
in general payments reported to CMS, 2019-2025
24 companies · $5,110 in 2025
The $5,110 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.65 · 2024: $3,421 · 2025: $5,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,334 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,334.39 |
| Education | $218.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,133.05 | 2024-2025 | |
| Ucb, INC. | $850.56 | 2024-2025 | Bimzelx |
| Incyte Corporation | $672.40 | 2024-2025 | Opzelura |
| Janssen Biotech, INC. | $608.22 | 2024-2025 | Tremfya, Axert |
| Leo Pharma INC. | $564.95 | 2024-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $460.86 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $448.68 | 2024-2025 | |
| Lilly USA, LLC | $387.00 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $385.26 | 2024-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $320.63 | 2024-2025 | |
| Galderma Laboratories, L.P. | $265.32 | 2024-2025 | Nemluvio, Aklief, Twyneo |
| Regeneron Healthcare Solutions, INC. | $219.70 | 2023-2025 | Dupixent |
| Organon LLC | $205.81 | 2025 | Vtama |
| Journey Medical Corporation | $205.50 | 2024-2025 | |
| Biofrontera INC. | $150.74 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $112.36 | 2024-2025 | |
| Pfizer INC. | $110.87 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Dermavant Sciences, INC. | $92.34 | 2024 | Vtama |
| Fresenius Kabi USA, LLC | $92.33 | 2024-2025 | Idacio, Adalimumab-Aacf |
| Verrica Pharmaceuticals INC. | $68.90 | 2024-2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $62.19 | 2025 | Zoryve |
| Strata Skin Sciences, INC. | $20.83 | 2025 | Xtrac |
| Paratek Pharmaceuticals, INC. | $13.98 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Thimons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.